Premium
Antipsychotic augmentation in depression linked with mortality risk, study suggests
Publication year - 2021
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30676
Subject(s) - medicine , depression (economics) , antidepressant , antipsychotic , food and drug administration , cohort , psychiatry , cohort study , schizophrenia (object oriented programming) , pharmacology , anxiety , economics , macroeconomics
Antipsychotic augmentation in patients with depression who received an antidepressant for 90 days was associated with a higher risk of mortality than adding a second antidepressant, a cohort study involving nonelderly adults has found. Previous findings of mortality risk associated with use of newer antipsychotics in the elderly led to a black box warning on the medications from the Food and Drug Administration (FDA). Results of the latest study were published online Sept. 30, 2020, in PloS One .